SUCLG1 Deficiency Links Metabolic Rewiring to Epigenetic Control in AML

Study Background and Research Question

Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy characterized by uncontrolled proliferation of myeloid progenitor cells. While multiple genetic and epigenetic drivers of AML have been identified, the metabolic reprogramming of leukemia cells—particularly their reliance on mitochondrial oxidative phosphorylation—has gained prominence as a defining feature and potential therapeutic target. Notably, chemotherapy-resistant AML cells often depend on mitochondrial function for energy production and survival, making the mitochondrial tricarboxylic acid (TCA) cycle a focus for new intervention strategies.

One TCA cycle enzyme, succinyl-CoA synthetase (SCS), composed of the alpha subunit SUCLG1 and a beta subunit (SUCLA2 or SUCLG2), is critical for the reversible conversion of succinyl-CoA to succinate, a process intimately linked to cellular energy balance. Recent observations suggest that SCS regulates not just metabolic flux but also post-translational modifications such as succinylation, which may impact nuclear events and gene expression. Building on these insights, Gao et al. (2025 Cell Reports) set out to delineate how SUCLG1 deficiency and associated metabolic changes modulate epigenetic regulation and leukemogenic gene expression in AML.

Key Innovation from the Reference Study

The central innovation of Gao et al.'s study is the mechanistic elucidation of how mitochondrial metabolic defects—specifically SUCLG1 loss—drive global protein and histone hypersuccinylation, leading to impaired oncogene expression in AML. By linking mitochondrial metabolism to chromatin regulation through the accumulation of succinyl-CoA and subsequent histone succinylation, the authors demonstrate that metabolic alterations can directly influence epigenetic landscapes and transcriptional outputs. This metabolic-epigenetic axis is shown to disrupt the interaction between BRD4 (a key chromatin reader involved in oncogenic transcriptional programs) and chromatin, thereby attenuating leukemia proliferation and progression both in vitro and in vivo.

Methods and Experimental Design Insights

To interrogate the role of SUCLG1 in AML, the authors utilized a multifaceted approach combining primary patient samples, cell lines, and animal models. Key methodological highlights include:

• Quantification of SUCLG1 expression and global protein/histone succinylation in primary AML samples using Western blot and mass spectrometry-based proteomics.
• Genetic depletion of SUCLG1 in AML cell lines via CRISPR/Cas9-mediated knockout or shRNA knockdown, followed by assessment of succinylation status and proliferation assays.
• Chromatin immunoprecipitation (ChIP) and chromatin fractionation to probe the interaction of BRD4 with chromatin in the context of altered succinylation.
• Transcriptomic profiling (RNA-seq) to capture changes in oncogene expression upon SUCLG1 deficiency and histone succinylation.
• In vivo leukemia models (xenografts in immunodeficient mice) to evaluate the consequences of SUCLG1 loss on disease progression, using bioluminescence imaging for non-invasive tracking of tumor cell burden.

The integration of in vivo bioluminescence imaging enabled real-time monitoring of leukemia progression, underscoring the importance of sensitive imaging substrates and luciferase reporter assays in translational oncology workflows.

Protocol Parameters

• SUCLG1 knockdown/knockout: Lentiviral transduction (MOI variable by cell type), followed by puromycin selection (1–2 μg/mL, 3–5 days) to enrich for edited cells.
• Assessment of protein/histone succinylation: Western blot with anti-succinyllysine antibodies; mass spectrometry for site-specific mapping.
• In vivo imaging: Luciferase-expressing AML cells injected into NSG mice; bioluminescence imaging performed after D-Luciferin (potassium salt) administration (typically 150 mg/kg, intraperitoneal injection, 10–15 min prior to imaging).
• BRD4-chromatin interaction: ChIP using anti-BRD4 antibodies; qPCR or sequencing to quantify chromatin-bound fractions.
• Gene expression analysis: RNA extraction followed by RNA-seq or qPCR validation.

Core Findings and Why They Matter

Gao et al. provide compelling evidence that SUCLG1 deficiency in AML cells triggers a marked increase in both global protein and histone succinylation. This hypersuccinylation, in turn, impairs the binding of BRD4 to chromatin—a key step required for the transcription of oncogenic programs. As a result, SUCLG1-deficient cells exhibit reduced expression of BRD4-dependent oncogenes, decreased cell proliferation, and delayed leukemia progression in xenograft models (reference study).

Mechanistically, the authors propose that histone succinylation competes with acetylation at lysine residues, thereby disrupting the recognition and binding of BRD4's bromodomain to chromatin. This not only attenuates leukemogenic transcriptional programs but may also restore regulatory balance to gene expression networks that are otherwise dysregulated in AML. The study positions metabolic-epigenetic crosstalk—specifically, the succinyl-CoA/histone succinylation axis—as a fundamental determinant of AML pathogenesis and a potential vulnerability for therapeutic exploitation.

Comparison with Existing Internal Articles

Several recent articles provide complementary perspectives on the use of D-Luciferin potassium salt and related bioluminescence imaging strategies in preclinical leukemia research:

• "D-Luciferin (Potassium Salt): Precision in Epigenetic AML Imaging" explores how D-Luciferin potassium salt enables advanced, quantitative in vivo bioluminescence imaging for studies at the intersection of epigenetics and metabolism in AML. The findings by Gao et al. validate and extend these systems-level imaging approaches by applying them to track disease progression in SUCLG1-deficient AML xenografts.
• "Reliable Bioluminescence: Solving Real Lab Challenges with D-Luciferin (Potassium Salt)" addresses the technical nuances and protocol optimizations required for reproducible in vivo imaging and luciferase reporter assays. The reference study’s use of bioluminescence imaging for real-time tumor cell tracking highlights the critical role of high-purity, water-soluble substrates such as D-Luciferin potassium salt in generating robust and interpretable data.
• The internal article "D-Luciferin (Potassium Salt): Catalyzing the Next Era of..." emphasizes workflow optimization and translational impact in animal models, aligning with the reference study's strategic integration of imaging modalities to investigate metabolic/epigenetic mechanisms in leukemia.

Collectively, these resources demonstrate the convergence of metabolic, epigenetic, and imaging innovations in contemporary AML research workflows.

Limitations and Transferability

While Gao et al. offer robust mechanistic insights, certain limitations should be acknowledged. The majority of experiments were conducted in established AML cell lines and immunodeficient mouse models, which may not fully recapitulate the complexity of human AML microenvironments. Moreover, although BRD4 is a major chromatin reader implicated in leukemogenic transcription, other bromodomain-containing proteins or co-factors may also be influenced by altered succinylation. The reversibility and therapeutic tractability of histone succinylation in clinical settings remain to be determined. Nevertheless, the study provides a clear rationale for targeting metabolic-epigenetic axes in AML and underscores the value of integrating in vivo bioluminescence imaging and luciferase reporter assays for dynamic, quantitative monitoring of disease progression and therapeutic response.

Research Support Resources

To facilitate workflows similar to those described in Gao et al., researchers can utilize D-Luciferin (potassium salt) (SKU C3654) from APExBIO as a reliable, water-soluble substrate for firefly luciferase. This compound is widely used for in vivo bioluminescence imaging in animal models, enabling sensitive, real-time tracking of tumor cells and disease progression. For best results, fresh solutions should be prepared as recommended in the product documentation and protocols tailored to specific model parameters. Additional optimization guidance and workflow comparisons can be found in internal articles focused on assay precision and imaging reliability. Integrating high-quality luciferase assay substrates such as D-Luciferin potassium salt ensures experimental robustness in both preclinical and translational research settings.